If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today

Gene-editing specialist Bluebird Bio (NASDAQ: BLUE) has been making plenty of noise since 2019, which is when it first earned marketing authorization for one of its breakthrough therapies, beta-thalassemia (TDT) treatment Zynteglo, in Europe. A lot has happened since then: It won more regulatory green lights in Europe and the U.S., but it had to exit the European market.

However, Bluebird stock hasn't been a particularly good investment in this period. Let's see how much people who bought $1,000 worth of the company's shares in early 2019 would have today and what it means for investors going forward.

BLUE Total Return Level data by YCharts.